Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), teer decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), teer decrease (Expand Search)
-
2541
-
2542
-
2543
Between-group differences in 95% Area, Y Sway Amplitude and LFS during postural training.
Published 2025Subjects: -
2544
-
2545
Consolidation of training-induced changes in unipedal stance: 95% Area, Y Sway Amplitude and LFS.
Published 2025Subjects: -
2546
-
2547
-
2548
-
2549
-
2550
-
2551
Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After accl...
Published 2025“…(c) Vitamin D3 and the positive control Cisplatin differently modulated FBG in hyperglycaemic mice: Intraperitoneal administration of vitamin D3 very minimally decreased FBG compared to vehicle control at the end of the study. …”
-
2552
The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells.
Published 2025“…<i>n</i> = 2–4 biological replicates per condition, with 15 individuals per replicate. Significance levels for Student <i>t</i> test are indicated for adjusted <i>p</i> values: *<i>p</i> < 0.05, ***<i>p</i> < 0.001, ***<i>p</i> < 0.0001. d: day(s), n.s.: non-significant. …”
-
2553
-
2554
Control (Ctrl) GECs are more susceptible to injury compared to iPLA<sub>2</sub>γ KO GECs.
Published 2024Subjects: -
2555
-
2556
Podocyte numbers in control and iPLA<sub>2</sub>γ KO mice (WT1-positive cells).
Published 2024Subjects: -
2557
-
2558
Receiver operating characteristic curve analyses for the prediction of hepatitis C.
Published 2025Subjects: -
2559
-
2560